Androgen receptor expression in triple-negative breast cancer

Detalhes bibliográficos
Autor(a) principal: Rodrigues, Filipa Nascimento
Data de Publicação: 2014
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/8288
Resumo: Dissertação de mestrado, Ciências Biomédicas, Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, 2014
id RCAP_2cf22179cc7403fa99e6205f1592511e
oai_identifier_str oai:sapientia.ualg.pt:10400.1/8288
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Androgen receptor expression in triple-negative breast cancerCiências biomédicasCancro de mamaPrognósticoMarcadoresTerapêuticasDomínio/Área Científica::Ciências Médicas::Ciências da SaúdeDissertação de mestrado, Ciências Biomédicas, Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, 2014Worldwide, 3 million the women are diagnosed with breast cancer which is the most common malignancy in female gender. Breast Cancer is a heterogeneous disease and clinically it is evaluated using three markers: the estrogen receptor (ER), the progesterone receptor (PR) and the epidermal growth factor receptor type 2 (HER2). The tumors that do not express any of these receptors are called triple-negative breast cancers (TNBC). TNBC represent approximately 20% of BC. These tumors constitute an important clinical challenge, as they do not respond to endocrine treatment and to anti HER2 directed therapy. As a group they harbor an aggressive clinical phenotype with early development of visceral metastases and a poor long-term prognosis. The only systemic treatment for TNBC is chemotherapy. Numerous experiments and trials have been done to try to understand what is targetable in TNBC and if so, if the clinical trials achieve their endpoints. Today, the trend in clinical practice is individualized treatment based on molecular biology markers of tumor and patient. Lehmann et. al. attempted to characterize TNBC and put forward a microarray signature that divides these tumors in 6 groups, according to differential gene expression profiles: basal-like 1 (BL1); basal-like 2 (BL2); immunomodulatory (IM); mesenchymal (M); mesenchymal stem–like (MSL) and luminal androgen receptor (LAR). Androgen receptor is member of the steroid hormone receptor family, expressed in more than 70% of breast cancers and has been implicated in breast cancer pathogenesis. The role of AR is of particular interest in patients with TNBC. In this project, immunohistochemistry was used to characterize the AR expression in a consecutive cohort of TNBC cases from Hospital CUF Lisboa. The immunohistochemical panels of markers used to characterize this subgroup of breast cancer, along with AR, were the CK 5/6, p-cadherin, PHH3 and EGFR in an attempt to further characterize TNBC subtypes. Of all the TNBC cases, 56% (28/50) were CK5/6, 0; 22% (11/50) were CK5/6, 1+; 12% (6/50) were CK5/6, 2+; and 10% (5/50) were CK5/6, 3+. In 96% (48/50) the expression of p-cadherin was positive while only 4% (2/50) was negative. Regarding EGFR, 38% (19/50) were EGFR, 0; 26% (13/50) were EGFR, 1+; 24% (12/50) were EGFR, 2+; and 12% (6/50) were EGFR, 3+. The expression of AR was considered positive in 62% of cases of TNBC. We have known from the literature that AR status is a significant independent prognostic factor, although we cannot show this in this sample. In this study was not possible to implement the Lehmann classification because it was not possible to separate the different TNBC by Immunohistochemical staining into 6 different categories of the Lehmann classification. The functional role of AR in breast cancer remains unclear, further exploration of this area could expand the repertoire of potential treatments for patients with AR+ TNBC.Braga, SofiaSapientiaRodrigues, Filipa Nascimento2016-05-19T13:15:31Z201420142014-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.1/8288TID:202211096enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:19:32Zoai:sapientia.ualg.pt:10400.1/8288Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:00:29.718557Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Androgen receptor expression in triple-negative breast cancer
title Androgen receptor expression in triple-negative breast cancer
spellingShingle Androgen receptor expression in triple-negative breast cancer
Rodrigues, Filipa Nascimento
Ciências biomédicas
Cancro de mama
Prognóstico
Marcadores
Terapêuticas
Domínio/Área Científica::Ciências Médicas::Ciências da Saúde
title_short Androgen receptor expression in triple-negative breast cancer
title_full Androgen receptor expression in triple-negative breast cancer
title_fullStr Androgen receptor expression in triple-negative breast cancer
title_full_unstemmed Androgen receptor expression in triple-negative breast cancer
title_sort Androgen receptor expression in triple-negative breast cancer
author Rodrigues, Filipa Nascimento
author_facet Rodrigues, Filipa Nascimento
author_role author
dc.contributor.none.fl_str_mv Braga, Sofia
Sapientia
dc.contributor.author.fl_str_mv Rodrigues, Filipa Nascimento
dc.subject.por.fl_str_mv Ciências biomédicas
Cancro de mama
Prognóstico
Marcadores
Terapêuticas
Domínio/Área Científica::Ciências Médicas::Ciências da Saúde
topic Ciências biomédicas
Cancro de mama
Prognóstico
Marcadores
Terapêuticas
Domínio/Área Científica::Ciências Médicas::Ciências da Saúde
description Dissertação de mestrado, Ciências Biomédicas, Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, 2014
publishDate 2014
dc.date.none.fl_str_mv 2014
2014
2014-01-01T00:00:00Z
2016-05-19T13:15:31Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/8288
TID:202211096
url http://hdl.handle.net/10400.1/8288
identifier_str_mv TID:202211096
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133229108690944

Registros relacionados